Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
about
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerNew perspectives in glioblastoma antiangiogenic therapyPharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaMEK and PI3K inhibition in solid tumors: rationale and evidence to dateOther targeted drugs in melanomaTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Treatment Individualization in Colorectal CancerPersistent androgen receptor addiction in castration-resistant prostate cancerTargeting RTK Signaling Pathways in CancerGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsTargeting the mTOR pathway in hepatocellular carcinoma: current state and future trendsPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerTargeted therapies in development for non-small cell lung cancerStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerTargeting the RAS oncogene.Therapeutic targeting of cancers with loss of PTEN function.CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagyElevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRMultimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responsePI3K at the crossroads of tumor angiogenesis signaling pathwaysComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesMulti-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cellsEvaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue SarcomasImaging biomarker roadmap for cancer studiesDeconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.How may targeted proteomics complement genomic data in breast cancer?Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Understanding, recognizing, and managing toxicities of targeted anticancer therapies.A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid TumorsLaser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.
P2860
Q26744721-6C2351D3-D707-4A3B-BF48-21704766054DQ26746028-B79EA8D7-2C0C-416D-835D-537C5418D30EQ26766292-14F5574A-A154-4EB2-B370-9379CF5F753AQ26766293-CE6F4499-057E-492B-963A-49DA83219A5EQ26775573-6BC63346-7EE9-4EBA-838A-7DB23C61E573Q26775594-7DA28472-FBA9-4013-9E01-21C5F0CD7D37Q26775940-1E595285-40D0-4F40-A181-AAC6523C51A8Q26776215-AE8521F9-BF05-45DB-ABBE-3EA4D1797D21Q26777163-EAEF4E72-2AD2-4946-A396-4BF7F7F80E2AQ26781278-C389BDC4-9A46-43E0-B7AF-86D74852755AQ26827975-E719F99D-4F67-4EA8-A68C-D5E8D9CEBA56Q26830194-DB7B467E-33DC-458F-89C8-2736B602A77CQ27006181-CEC2DCAF-2167-4F9D-B9C6-0C90FF9CCAD0Q27022852-D1B1FAE2-C589-4314-A07A-CCA5B604F46CQ27026544-7FFA74C9-B517-4965-B9BB-D5BCF9BD2C2CQ27315948-95E06D16-6CFB-46DE-8279-CFF1F1BDAB51Q27687198-4947D9EC-2033-4FCC-8ECE-8A832104E0A4Q27852764-50AC6ADC-EA71-44C1-A6EF-AE053AD085DDQ27853037-C691A6F4-2D17-4F81-A238-9975E1FB2FC9Q27853088-13F2F62A-854B-4E79-BB60-D6E702355B72Q27853104-A7F75C25-ECFB-4625-BC71-B4661CD2F962Q27853128-C3D7BE1F-E18B-42D7-89B8-63941D65A03FQ27853324-206C50EA-DFEC-45FF-AE50-CE8AA9698AE6Q28081735-BAE46E24-5F39-411A-AFC5-2DA2FB748BFFQ28084715-CB19DA25-0E01-4959-855A-8B282B1193FBQ28086993-1DC3D111-91BB-482C-A852-1AFF8BE31441Q28384680-7542E12D-DA9D-4926-9A32-0C025A582F44Q28396795-26467C03-FD42-4172-875E-E38E1FC1E243Q28397537-1C58BDD6-229A-4422-A89D-FCE3B5FB9DDDQ28480805-0B127762-A2B6-4606-AB56-D26EF12FD320Q28548425-6FDF09C1-18A1-46A3-9FDC-4967980989FEQ30242020-D24ED22A-4A27-468A-BDDD-1FDF54D32869Q30841629-800248C6-EB6B-4734-999F-3475C8FF2D87Q31106994-57765507-8027-41FC-8F5C-F1DEEC68C218Q31140924-550B3DD4-61F8-4350-A8A8-9247DBC08530Q33356339-392BF870-27EB-48B6-A0A2-93CA4B162BF2Q33408049-C906AD01-9A6E-4F55-A0C4-985C848439FEQ33426930-1B15E87E-2CFA-4F5B-ADF7-2477E9C2A97EQ33439962-6D31EAE9-2CC4-4E5B-AE49-BA71981E8FD3Q33462023-23AD8124-6160-412C-820D-3D2560CDF2DA
P2860
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase I, dose-escalation study ...... ts with advanced solid tumors.
@en
type
label
Phase I, dose-escalation study ...... ts with advanced solid tumors.
@en
prefLabel
Phase I, dose-escalation study ...... ts with advanced solid tumors.
@en
P2093
P356
P1476
Phase I, dose-escalation study ...... ts with advanced solid tumors.
@en
P2093
David Demanse
Diana Birle
Howard A Burris
Jaap Verweij
Johanna C Bendell
Jordi Rodon
José Baselga
Maja de Jonge
Malte Peters
Michael Goldbrunner
P304
P356
10.1200/JCO.2011.36.1360
P407
P577
2011-12-12T00:00:00Z